Deciphering the molecular networks that discriminate organ-confined breast cancer from metastatic breast cancer may lead to the identification of critical biomarkers for breast cancer invasion and aggressiveness. Here metabolomics, a global study of metabolites, has been applied to explore the metabolic alterations that characterize breast cancer progression. We profiled a total of 693 metabolites across 87 serum samples related to breast cancer (46 clinically localized and 41 metastatic breast cancer) and 49 normal samples. These unbiased metabolomic profiles were able to distinguish normal individuals, clinically localized and metastatic breast cancer patients. 9-cis-Retinoic acid, an isomer of all-trans retinoic acid, was identified as a differential metabolite that significantly decreased during breast cancer progression to metastasis, and its levels were also reduced in urine samples from biopsy-positive breast cancer patients relative to biopsy-negative individuals and in invasive breast cancer cells relative to benign MCF-10A cells. The addition of exogenous 9-cis-retinoic acid to MDA-MB-231 cells and knockdown of aldehyde dehydrogenase 1 family member A1, a regulatory enzyme for 9-cis-retinoic acid, remarkably impaired cell invasion and migration, presumably through preventing the key regulator cofilin from activation and inhibiting MMP2 and MMP9 expression. Taken together, our study showed the potential inhibitory role for 9-cis-retinoic acid in breast cancer progression by attenuating cell invasion and migration.
(ie, its "metabolome"), 4 which is a useful complement to the characterization of several physiological and pathological conditions and offers promise as a clinical tool for disease diagnosis and prediction. 5, 6 The metabolome can be considered the downstream end product of the complex interaction of genome, transcriptome and proteome, and affected by perturbations as a result of physiology, pathology and iatrogenic factors. 7, 8 Discovery of regulatory enzymes and genes through differential metabolites and the known pathways will help us to gain better understanding of dysregulated metabolism in disease initiation and progression.
Breast cancer has been associated with profound alterations in metabolic systems, which have been demonstrated in many preclinical and clinical metabolomics studies of breast cancer cells, tissues, serum and urine. [9] [10] [11] [12] For example, glutamate was found to successfully differentiate breast cancer patients from normal controls. 13 Plasma metabolic profiles of breast cancer patients showed that a panel of 8 differential metabolites, including carnitine, lysophosphatidylcholine (20:4), proline and alanine, was identified to distinguish between subtypes of breast cancer. 14 However, metabolomics biomarker and differential pathways are difficult to replicate among different studies, primarily as a result of the heterogeneity of patients and the different analytical and clinical protocols. 15, 16 Moreover, limited data are available to characterize the metabolomics changes during breast cancer progression by metabolic profiling of biospecimens.
Liquid chromatography coupled with mass spectrometry (LC/ MS), gas chromatography coupled with mass spectrometry (GC/MS), and NMR are the three most commonly used techniques for metabolomics studies. 17, 18 LC/MS and GC/MS techniques have the advantage of higher sensitivity 19 and greater separation efficiency, respectively. 20 Combined use of LC/MS and GC/MS could be a better choice to profile different classes of metabolites.
In the present study, metabolomics was applied to identify the distinct metabolite signatures of patients with metastatic breast cancer and screen the metabolic markers associated with breast cancer metastasis, which could provide a theoretical basis for early diagnosis, prognosis evaluation and therapeutic target research of breast cancer. The initial training study was conducted with the use of 46
clinically localized breast cancer serum samples (LC), 41 metastatic breast cancer serum samples (MT), and 49 normal control samples (NC), which were profiled using ultra-performance liquid chromatography-linear ion trap mass spectrometry (UPLC-LTQ/MS), and further validated with 50 LC and 50 MT profiled using gas chromatography-triple quadrupole mass spectrometry (GC-QQQ/ MS). Moreover, breast cancer urine samples and invasive breast cancer cells were used to support the identified metabolic feature. 
| MATERIALS AND METHODS

| Cells, reagents, and instruments
| Sample collection
All samples were collected from Tianjin Medical University Cancer
Institute & Hospital with informed consent according to approval of the Institutional Review Board. Detailed clinical characteristics of serum samples used in the profiling phase of this study are provided in Table 1 . Analogous characteristics for urine samples used in the validating phase of this study are given in Table S1 . All samples were stored at À80°C until use.
| Sample preparation
Serum sample (100 lL each) was mixed with 400 lL methanol to precipitate proteins, and then centrifuged (4°C, 15 000 g, 30 minutes). The supernatant was filtered using a 0.22-lm membrane and detected by LC/MS.
Serum and urine samples were centrifuged at 4°C, 15 000 g for 30 minutes, and the supernatant was extracted with 1 mL degassed isopropanol/acetonitrile/water (3/3/2) at 4°C for 5 minutes. The extracts were subsequently dried down and resuspended in 50% aqueous acetonitrile to remove most of the complex lipids. After dry evaporation, extracts were derivatized and subjected to GC/MS analysis.
As part of the quality control (QC) and system conditioning process, a pooled QC sample was prepared by mixing equal volumes (20 lL) of each sample.
| Liquid chromatography coupled with mass spectrometry analysis
The chromatography system was equipped with a binary solvent delivery manager, and a sample manager. Chromatographic separation was carried out using a gradient of ACN : water (both solvents were modified by the addition of 0.1% formic acid) from 5% to 95% over a 10-minute period, followed by 95% ACN for 4 minutes. Then, the chromatographic elution gradient was immediately reduced to 5% ACN, which was used to balance the analytical column (Hypersil GOLD C-18; Thermo Fisher) for the final 4 minutes. The LTQ Orbitrap XL hybrid MS 21 was set for continuous monitoring of positive ions, and data were collected over 15 minutes in centroid mode over the mass range 50-1000 m/z. MS resolution was at 100 000 full-width halfmaximum (FWHM) and the calibration standards (caffeine, Ultramark 1621) were used to assure chromatographic consistency.
| Gas chromatography coupled with mass spectrometry analysis
Samples were redried under vacuum desiccation for a minimum of 24 hours prior to being derivatized under dried nitrogen using bis(trimethylsilyl)trifluoroacetamide (BSTFA). During the course of the run, temperature was ramped from 80°C to 300°C in a 35-minute period, followed by 300°C for 8 minutes. Collision gas velocity was 2.25 mL/min for helium and 1.5 mL/min for nitrogen. QQQ mass spectrometry was set for continuous monitoring of positive ions using electron impact ionization and high resolution.
Level of target metabolite was quantified by selected ion monitoring (SIM) using isotope dilution electron-impact ionization GC/ MS, and relative area counts were obtained by manual integration of its chromatogram peaks using Xcalibur software. Association between metabolite expression level and cell invasiveness was assessed by Pearson correlation coefficients. Hierarchical clustering was carried out on the log transformed normalized data using the MeV software package (version 4.9.0).
| Statistical analysis
| Metabolomics pathway analysis
Database sources including the Human Metabolome Database, KEGG and MetaboAnalyst were used for the identification of altered metabolic pathways.
| RNA interference
Following the manufacturer's instructions, transient transfection was carried out by using Lipofectamine 2000 (Invitrogen) with 
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LC, clinically localized breast cancer serum group; MT, metastatic breast cancer serum group; NC, normal control serum group. "-" represents the number is 0.
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| 2317 ALDH1A1-specific siRNA (insert CATGATTCAGTGAGTGGCAA-GAAAT) and scramble sequence siRNA from Invitrogen. BLOCK-iT Fluorescent Oligo was used to examine transfection efficiency (Invitrogen). Seventy-two hours after transfections, cells were harvested and used for further experiments.
| Reverse transcription-PCR
Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA).
For the RT-PCR, the One Step RNA PCR Kit (AMV) was used (TaKaRa, Dalian, China). The PCR procedure was done at 94°C for 1 minute, at 56°C for 1 minute and at 72°C for 1 minute with a total of 35 cycles.
Specific primers for GAPDH (forward, 5 0 -GCCACTAGGCGCT-
reverse, 5 0 -CATTGACTCCATTGTCGCCAG-3 0 ) were from TaKaRa.
| Western blotting assay
Western blotting assay was carried out as described by Sun et al. 24 Briefly, cells were lysed by 19 SDS lysis buffer (Tris-HCl, pH 6.8,
mM, 2% SDS, 10% glycerol). Equal amounts of cell lysates
(20 lg per lane) were loaded onto 10% SDS-PAGE systems and transferred onto PVDF membranes (Immobilon-P; Millipore, Burlington, MA, USA). The membranes were probed with primary antibodies followed by HRP-conjugated secondary antibody and visualized by using ECL reagents (Pierce, Rockford, IL, USA).
| Proliferation assay
Cells were exposed to different concentrations of 9-cisRA for 24
and 48 hours in 96-well plates. Proliferation assay was carried out as described by the manual of CCK-8 (CK04; Dojindo, Kumamoto, Japan).
| Invasion assay
Cell invasion assay was done as previously described. 25 Figure S1A . Stability of the UPLC/MS system was adequately assessed by the analysis of QC samples during the entire experimental period. 26 From the QC principal component score plot ( Figure S1B ) we found that the UPLC/MS system was stable throughout the analytical process.
A total of 693 metabolites were quantified from the detected spectral features of serum samples, of which 79.8% (553/693) were shared by the 3 groups ( Figure 1A) . Notably, there were 69 metabolites found in the LC and/or MT group but not in the NC group.
These profiles are displayed as a heat map ( Figure 1B ) and as an NC-based z-score plot for each of the 693 metabolites ( Figure 1C ).
The z-score plots showed robust metabolic alterations in the MT group (z-score range: À5.63 to 15.32) compared to fewer changes in LC group samples (z-score range: À3.94 to 8.81).
Principal component analysis was carried out to assess the separation tendency between groups based on the 693 annotated metabolites. As shown in Figure 2A , Figure 2D ) and at 0.786/À0.623 (Figure 2G) , respectively, indicating that no over-fitting was observed.
Performance of the OPLS-DA models was further tested in another group of 50 clinically localized breast cancer serum samples, 50 metastatic breast cancer serum samples and 50 normal control samples, and all test samples were correctly classified by the OPLS-DA models.
The metabolites with VIP in the project higher than 1 in OPLS-DA models, and the metabolites with a high degree of variation (high horizontal ordinate value) and reliability (high vertical ordinate value) from the s-plots ( Figure 2E ,H) were selected as differential variables between NC and LC groups, and between LC and MT groups. Additionally, the 2-tailed Wilcoxon rank-sum test was used to validate the significance of the difference in intensities between variables. Figure 3A . Among the perturbed metabolites, 26 were elevated in LC whereas 31 were downregulated. Figure 3B shows the relative levels of the 46 named metabolites that were differential between NC and LC groups. Similarly, 13 metabolites were found to be elevated in the MT samples compared to the LC samples whereas 8 metabolites were downregulated (P < .05) (Table S2 ). cantly elevated upon disease progression from NC to LC to MT whereas 9-cisRA was markedly downregulated (Table 2) . These metabolites could potentially serve as biomarkers for breast cancer progression, and 9-cisRA was the most significant differential metabolite between groups (Figure 4) . Moreover, 9-cisRA was found to be significantly lower in urine supernatants (n = 55, P = 4.354E-17) derived from biopsy-positive breast cancer patients as compared to negative individuals (n = 54) ( Figure 5A ). Overall receiver operator characteristic (ROC) curve for 9-cisRA suggested its predictive value was modest with the area under the curve (AUC) of 0.71 (95% CI: 0.53, 0.88) for urine supernatants (Fig- ure 5B).
Using MetaboAnalyst 3.0 (http://www.metaboanalyst.ca/Metab oAnalyst/), the key metabolic pathways dysregulated in breast cancer patients were identified as retinol metabolism, glycerophospholipid metabolism, sphingolipid metabolism and pyrimidine metabolism. Among these, the retinol metabolic pathway had the most differential metabolite 9-cisRA and showed a profound change ( Figure 5C ).
| 9-cis-Retinoic acid levels correlated with breast cancer cell invasion
To determine whether 9-cisRA decrease in breast cancer has biological relevance, we measured its endogenous levels in breast cancer cell lines MDA-MB-231, MDA-MB-468 and MCF-7 (n = 3 each), and benign MCF-10A breast cells (n = 3). Significantly reduced levels of the metabolite were found in breast cancer cells compared to benign MCF-10A cells (ANOVA, P = 2.571E-6). Additionally, 9-cisRA levels negatively correlated with cell invasiveness (Pearson correlation = À.988, P = .0124) ( Figure 6A ).
Cell proliferation assay was then carried out to test the cytotoxic effect of exogenous 9-cisRA against the MDA-MB-231 and MCF-7 cells. As shown in Figure 6B , gradient concentrations of 9-cisRA (25, 50, 100, and 200 lmol/L) had no significant effects on cell proliferation after 24-and 48-hour treatments until the concentration of 9-cisRA was increased to 500 lmol/L where cell proliferation was obviously inhibited.
To investigate the inhibitory effect of 9-cisRA (50, 100, and 200 lmol/L) on the invasion and migration of cells, we carried out Matrigel invasion and scratch assays. As shown in Figure 6C Comparison of characteristic metabolites' integral peak area in the 3 groups. Non-parametric test was used for comparisons among the groups (*P < .05, **P < .01).
and invasion. 27, 28 As shown in Figure 6F , phosphorylation of cofilin was obviously reduced in the combined siALDH1A1 + 9-cisRA (200 lmol/L) group compared to the control, siALDH1A1 and 9-cisRA groups. As the expression of MMP is crucial to ECM degradation and cell invasion, it is vital to determine whether MMP are involved in the inhibition of migration and invasion by siALDH1A1 and 9-cisRA treatments. As shown in Figure 6F , MMP2 expression was moderately reduced in the siALDH1A1, 9-cisRA and combined siALDH1A1 + 9-cisRA groups in comparison to the control group.
Also, MMP9 expression was significantly inhibited by combined siALDH1A1 + 9-cisRA treatment compared to all other groups.
Taken together, our data suggest that siALDH1A1 and 9-cisRA coordinately inhibited breast cancer cell invasion by attenuating the phosphorylation of cofilin and the expressions of MMP2 and MMP9. results indicated that 9-cisRA offered high accuracy in a heterogeneous validation set of breast cancer patients, and its potential utility will be further validated in a larger patient population.
| DISCUSSION
9-cis-Retinoic acid, an isomer of all-trans retinoic acid, is produced from 9-cis-retinal by an oxidation process. It participates in retinol metabolism and can also be converted to 9-cis-retinal by specific regulatory enzymes. 9-cisRA which binds to both retinoic acid receptors (RAR) and nuclear retinoid X receptors (RXR) prevented prostate carcinogenesis in rats, reduced growth and induced apoptosis of human prostate cancer cells in a dose-dependent method. 33 9-cisRA induced the downregulation of P-glycoprotein, 40 and it has been proposed as a potential target for anti-breast cancer therapy. Our study found that knockdown of ALDH1A1 in MDA-MB-231 cells increased intracellular 9-cisRA levels while notably suppressing the invasive abilities of breast cancer cells.
Furthermore, our data indicated that the synergistic effect of siALDH1A1 and 9-cisRA against cell migration was a result of its blocking phosphorylation of the key regulator cofilin, the activity of which is pivotal for actin-polymerization and cell migration. 41 Moreover, we also found that expressions of MMP2 and MMP9, which F I G U R E 5 Lowered level of 9-cis-retinoic acid (9-cisRA) is a metabolic feature of human breast cancer, and the disturbed metabolic pathways in breast cancer patients compared with healthy controls. A, Boxplot showing significantly lower level of 9-cisRA in 55 biopsypositive breast cancer urine samples compared to 54 biopsy-negative controls (**P = 4.354E-17). B, Receiver operator characteristic curve for 9-cisRA in the 109 urine supernatants. 9-cisRA has an area under the curve (AUC) of 0.71 (95% CI: 0.53, 0.88). C, MetaboAnalyst-generated topology map describes the impact of differential metabolites identified between breast cancer patients vs healthy controls on metabolic pathways are 2 important members of the MMP family and can degrade the ECM at tumor-invasive fronts to overcome the ECM barrier and subsequently facilitate cancer metastasis, 42, 43 were significantly inhibited attributable to the anti-invasive effects of siALDH1A1 and 9-cisRA treatments. Therefore, the results presented here have established at least part of the mechanism of siALDH1A1 and 9-cisRA in preventing migration and invasion of breast cancer cells.
Taken together, we explored the metabolomic signatures during breast cancer progression. Specifically, we identified 9-cisRA as a key metabolite that decreased most robustly in metastatic breast cancer and was detectable in the urine of patients with metastatic disease. Interestingly, 9-cisRA, and its proximal regulatory enzyme, appear to play an inhibitory role in neoplastic progression attenuating cell invasion and migration, presumably through preventing the key regulator cofilin from activation and inhibiting the expressions of MMP2 and MMP9. Thus, 9-cisRA and its proximal regulatory enzyme may have potential as biomarkers of breast cancer progression as well as exerting an inhibitory role in breast cancer progression. In the future, we will undertake a study of a larger prospective cohort to further validate the accuracy of our research. An F I G U R E 6 9-cis-Retinoic acid (9-cisRA) levels in breast cancer cells and its association with invasion and migration. A, Decreased levels of 9-cisRA (black bars) were found in invasive breast cancer cells compared to non-invasive benign MCF-10A cells. Mean AE SEM of 9-cisRA levels (n = 3). Cell invasion (grey bars) was measured. B, Assessment of the effects of 9-cisRA on MDA-MB-231 and MCF-7 cell proliferation. C, Assessment of MDA-MB-231 and MCF-7 cell invasiveness upon giving exogenous 9-cisRA. Photographs were taken at a magnification of 2009 (eg, MDA-MB-231). D, Assessment of MDA-MB-231 cell migration upon giving exogenous 9-cisRA. E, RT-PCR and western blotting analysis of aldehyde dehydrogenase 1 family member A1 (ALDH1A1) in MDA-MB-231 (left panel) and assessment of 9-cisRA levels and cell invasiveness after knockdown of ALDH1A1 (right panel). F, Western blotting analysis of P-cofilin, MMP2 and MMP9 from the 4 treatment groups. Each result is a representative of at least 3 independent experiments. *P < .05; **P < .01 evaluation of 9-cis-RA levels and the mechanisms of breast cancer metastasis by tissue-targeted metabolomics as well as other systematic biological approaches could be used. We also thank the participants in this study.
ACKNOWLEDGMENTS
CONF LICTS OF INTEREST
Authors declare no conflicts of interest for this article.
O R C I D
Jing Wu
http://orcid.org/0000-0002-7020-2797
